Abstract
Abstract Breast cancer is the most common malignancy that occurs in women in the US and has the second highest cancer-associated mortality rate. Depending on the expression of estrogen receptor α (ERα), breast cancer can be classified as ER positive or negative. Current drugs used to treat ER+ cancers include selective estrogen receptor modulators (SERMs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, prolonged exposure to these drugs often leads to the development of acquired resistance. Consequently, there is a great need to develop alternative therapeutic options. Flexible heteroarotinoids (Flex-Hets) are compounds derived from retinoids that have been shown to display anti-cancer activity. These compounds tend to exhibit lower toxicity in comparison to their retinoid precursor. The objective of this study is to investigate the anti-cancer effects of SL1-18 — a novel heteroarotinoid — on ER+ breast cancer. Our data suggest that treatment of MCF-7 with SL1-18 inhibit cell growth with a GI50 of 5μM. In order to understand the mechanism of action, we evaluated the effects of SL1-18 on the expression of cell cycle regulators, and our results suggest that SL1-18 decreases the expression of cyclin A, cyclin B, cyclin D1 and cdk2. Furthermore, cell cycle analysis revealed that SL1-18 reduces the number of cells going through the S phase when compared to mock-treated controls. Taken together, these preliminary results suggest that the SL1-18 may be a potent inhibitor of breast cancer cell growth, but further research is necessary to determine its mechanism of action. Citation Format: Maryam Fallatah, Maggie C. Louie, Shengquan Liu. Inhibition of breast cancer cell proliferation by diarylthiourea analog, SL1-18. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1775. doi:10.1158/1538-7445.AM2015-1775
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
